Vaccinex Reconciled Depreciation from 2010 to 2024

VCNX Stock  USD 3.69  0.13  3.65%   
Vaccinex Reconciled Depreciation yearly trend continues to be fairly stable with very little volatility. Reconciled Depreciation is likely to outpace its year average in 2024. During the period from 2010 to 2024, Vaccinex Reconciled Depreciation regression line of annual values had r-squared of  0.03 and arithmetic mean of  207,413. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2017-03-31
Previous Quarter
26 K
Current Value
24 K
Quarterly Volatility
16.5 K
 
Covid
Check Vaccinex financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaccinex's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 19.7 K or Depreciation And Amortization of 181 K, as well as many indicators such as Price To Sales Ratio of 7.19, Dividend Yield of 0.0 or Days Sales Outstanding of 451. Vaccinex financial statements analysis is a perfect complement when working with Vaccinex Valuation or Volatility modules.
  
Check out the analysis of Vaccinex Correlation against competitors.
For more information on how to buy Vaccinex Stock please use our How to Invest in Vaccinex guide.

Latest Vaccinex's Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of Vaccinex over the last few years. It is Vaccinex's Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaccinex's overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Pretty Stable
   Reconciled Depreciation   
       Timeline  

Vaccinex Reconciled Depreciation Regression Statistics

Arithmetic Mean207,413
Geometric Mean204,383
Coefficient Of Variation18.06
Mean Deviation20,901
Median206,000
Standard Deviation37,465
Sample Variance1.4B
Range170K
R-Value(0.17)
Mean Square Error1.5B
R-Squared0.03
Significance0.55
Slope(1,409)
Total Sum of Squares19.7B

Vaccinex Reconciled Depreciation History

2024171.2 K
2023137 K
2022207 K
2021169 K
2020307 K
2019249 K
2018223 K

About Vaccinex Financial Statements

Vaccinex investors use historical fundamental indicators, such as Vaccinex's Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaccinex. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Reconciled Depreciation137 K171.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaccinex Stock Analysis

When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.